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Human hepatic stem cells transplanted into a fulminant hepatic failure 
Alb-TRECK/SCID mouse model exhibit liver reconstitution and drug metabolism 
capabilities 
 
1. Introduction 
“Humanized” mouse models exhibited responses to drugs similar to those of the human liver. 
Current mouse models used for humanized liver generation are primarily uPA+/+ (uroplasminogen 
activator) mice (Tateno et al., 2004), Fah−/− (fumarylacetoacetate hydrolase) mice (Azuma et al., 
2007), and a recently reported TK-NOG (thymidine kinase) mouse. However, previous reports 
showed that transplanted human immature cells or stem cells were less competitive as compared 
with human adult hepatocytes in Alb-uPAtg(+/−)Rag2(−/−) mouse livers (Peltz, 2013). Moreover, 
Fah−/− mice could only provide a growth advantage for differentiated hepatocytes but not for 
immature liver progenitor cells (Zhu et al., 2014). To overcome this problem, we report here on a 
novel Alb-TRECK/SCID mouse model that could be efficiently repopulated with human immature 
hepatocytes. This transgenic mouse expresses human heparin-binding EGF-like growth factor 
(HB-EGF) receptors and developed fulminant hepatitis administering diphtheria toxin (DT) (Saito et 
al., 2001). In this study, we generated humanized livers in Alb-TRECK/SCID mice by transplanting 
human primary fetal liver cells (FLCs) and hepatic stem cells (HpSCs). 
2. Material and methods 
1.5 µg/kg diphtheria toxin (DT) was administrated into 8-week-old Alb-TRECK/SCID mice, 
and the degree of liver damage was assessed by serum aspartate aminotransferase (AST) activity 
levels. Forty-eight hours later, mice livers were sampled for histological analyses, and the human 
donor cells were then transplanted into mice livers on the same day. Chimeric rate and survival rate 
after cell transplantation was evaluated. Expressions of human hepatic related genes were detected. 
A human albumin ELISA was done after 50 days of transplantation. On day 60 after transplantation, 
drug metabolism was examined in mice. 
3. Results and discussion 
DT induces lethal fulminant hepatic failure in Alb-TRECK/SCID mice. 
The mouse serum AST activity reached a peak at 48 h after DT injection and then returned 
toward basal levels by 96 h. Histological analysis exhibited that after administration of DT, there 
was a disorganized hepatic architecture showing a correction for congestion with the increased 
serum AST activity, and hepatocytes also had multiple, deeply stained acidophilic cytoplasmic 
inclusions along with dark nuclei (most probably apoptotic hepatocytes). These results were in 
agreement with those of a previous study that showed that Alb-TRECK/SCID mice were an ideal 
lethal fulminant hepatic failure model generated by only a single DT injection (Saito et al., 2001).  
Alb-TRECK/SCID mice with lethal fulminant hepatic failure are rescued by human hepatic 
stem cell transplantation. 
Mice with AST activity levels between 12000 and 16000 IU/L were used as recipients and were 
transplanted with 1 x 106 cells, either human primary FLCs or HpSCs. More than 60% of human 
HpSCs transplanted mice survived for more than 120 days, whereas all of the human primary FLCs 
transplanted mice were dead within 110 days. Histological examination showed that both human 
primary FLCs and HpSCs had reconstituted the liver structure by replacing original mouse 
hepatocytes (Figure 1). These results showed that mice with human primary FLCs transplantation 
survived over a short term, whereas for long-term survival, transplanted human HpSCs might have 
been functional. 
Proliferative human HpSCs successfully differentiate in humanized livers of 
Alb-TRECK/SCID mice. 
Human primary FLCs derived liver sections that were positively stained with human CK8/18 
were human ALB and CK19 negative, whereas human HpSCs-derived human hepatocytes in mouse 
livers were well differentiated and with upregulated human ALB expression. Human ALB positive 
hepatocytes that were CK19 negative resembled functional hepatocytes, while cells that positively 
co-stained with human ALB and CK19 exhibited a bipotential capability with differentiation into 
hepatocytes and cholangiocytes. These results unveiled that as compared with human primary FLCs, 
human HpSCs had a high potential for differentiation into functional hepatocytes in vivo in response 
to the rescue of damaged mouse liver functions. 
Characterization of human drug metabolism gene expression in Alb-TRECK/SCID mouse 
with humanized livers.  
We also evaluated human drug metabolism related gene expression after 8 weeks of cell 
transplantation, we observed very high gene expression levels associated with the human hepatic 
functional markers ALB, AFP, and cytochrome P450, including CYP3A4, 2C9, and 2C19, which 
collectively metabolize over 80% of clinical drugs. Microarray analysis for 83 previously reported 
human drug metabolism related genes and 38 mature hepatocyte specific genes whose expressions 
were robustly increased in humanized livers. These results indicated that relevant functional human 
drug metabolizing enzymes were expressed in humanized livers derived from human HpSCs, which 
could be useful for preclinical drug development. 
Functional characterization of humanized livers in Alb-TRECK/SCID mice.  
At about 8 weeks after transplantation, the level of liver repopulation with human donor cells 
and human ALB concentrations in mouse sera were determined. Humanized livers derived from 
human HpSCs resulted in more human ALB secretion than those from human primary FLCs, and no 
human ALB could be detected in mice after saline transplantation. The drug metabolism profiles 
based on gene expression and human ALB secretion patterns suggested the potential of humanized 
livers derived from human HpSCs for early identification of major drug metabolites in vivo. We 
administered ketoprofen (KTP) and debrisoquine (DEB). The fold-change of KTP-glu/M1 was 
significantly greater in human HpSCs- derived humanized livers than in human primary FLCs- 
derived humanized livers and sham-treated mice. For DEB, a higher metabolic ratio of 
4OH-DEB/DEB was detected in human HpSCs-derived humanized livers.  
These results showed that human HpSCs-derived humanized livers would be advantageous for 
improving the quality of human drug metabolism and for preclinical studies.  
 
Figure 1. Morphology of humanized livers derived from HpSCs, Image of a macroscopic whole 
mouse liver 1 month after transplantation of human EGFP-HpSCs. 
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